This proposal examines the nature of circulating immunoreactive insulin in the insulin dependent diabetic. It is generally assumed that injected insulin is absorbed from the subcutaneous tissues intact. However, we have discovered an insulin-like substance, twice the size of insulin, in the circulation of nearly every diabetic tested to date in our laboratory. This insulin-like material (ILM) shares many of the characteristics of an insulin dimer and it may be formed in the subcutaneous tissues. The amount of ILM varies widely but can account for nearly 50% of the total insulin immunoreactivity detected in the blood of the type I diabetic. There seems to be more of this material in patients using beef-containing insulin and considerably less in those who use biosynthetic human insulin. It is tempting to hypothesize that the relative solubility of human insulin prevents the formation of this high molecular weight product.
The specific aims of this proposal are to characterize this novel product of therapeutic insulin and determine its physiologic or pathophysiologic consequences on the insulin-requiring diabetic. There are reasons to be concerned that this material may have deleterious effects on the diabetic. First, insulin dimers and high molecular weight insulin products may act as potent antigens, immunizing the diabetic against insulin and resulting in the production of anti-insulin antibodies. Second, insulin dimers probably lack biologic activity and they may act as true competitive antagonists to insulin. This could cause or contribute to a state of insulin resistance and suboptimal diabetic control. Third, these """"""""foreign"""""""" proteins may play a primary role in the production of diabetic end-organ complications. ILM will be measured in diabetics during treatment with various types of insulin given by the subcutaneous and intravenous routes. Hyperinsulinemic, euglycemic clamps will be performed in normal and diabetic volunteers to determine any in vivo role for ILM in insulin resistance. Biologic activity of ILM will be tested in vito using the isolated adipocyte method. A major effort will be directed towards characterizing the material and offering a structural determination. Finally, there will be a preliminary attempt to determine whether there is any relationship between ILM and end-organ damage in a retrospective fashion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK)
Type
Research Project (R01)
Project #
5R01AM034101-02
Application #
3153060
Study Section
Metabolism Study Section (MET)
Project Start
1984-08-01
Project End
1987-07-31
Budget Start
1985-08-01
Budget End
1986-07-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Vermont & St Agric College
Department
Type
Schools of Medicine
DUNS #
066811191
City
Burlington
State
VT
Country
United States
Zip Code
Calles-Escandon, J; Jaspan, J; Robbins, D C (1989) Postprandial oscillatory patterns of blood glucose and insulin in NIDDM. Abnormal diurnal insulin secretion patterns and glucose homeostasis independent of obesity. Diabetes Care 12:709-14
Tonino, R P (1989) Effect of physical training on the insulin resistance of aging. Am J Physiol 256:E352-6
Maislos, M; Bialer, M; Mead, P M et al. (1988) Pharmacokinetic model of circulating covalent aggregates of insulin. Diabetes 37:1059-63
Robbins, D C; Hirshman, M; Wardzala, L J et al. (1988) High-molecular-weight aggregates of therapeutic insulin. In vitro measurements of receptor binding and bioactivity. Diabetes 37:56-9
Robbins, D C; Jaspan, J; Vasquez, B et al. (1987) Biphasic patterns of peripheral insulin and glucose levels after lunch in normal subjects. Diabetes Care 10:293-9
Robbins, D C; Cooper, S M; Fineberg, S E et al. (1987) Antibodies to covalent aggregates of insulin in blood of insulin-using diabetic patients. Diabetes 36:838-41
Calles-Escandon, J; Robbins, D C (1987) Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes 36:1167-72
Robbins, D C; Mead, P M (1987) Free covalent aggregates of therapeutic insulin in blood of insulin-dependent diabetics. Diabetes 36:147-51
Maislos, M; Mead, P M; Gaynor, D H et al. (1986) The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin. J Clin Invest 77:717-23